Alendronate
Trovati 8 articoli
- Fosamax may be linked to atrial fibrillation
- Alendronate ( Fosamax ), a medication used to prevent fractures in women with osteoporosis, may be associated with an increased risk of atrial fibrillation. Other recent studies have reported atrial fibrillation as an unexpected adverse effect of bisphosphonates, a class of drugs that includes... (Leggi Articolo)
- Bone loss in breast cancer survivors: antitumor drugs aren't the only culprits
- Osteoporosis is a growing concern among breast tumor survivors, because certain cancer drugs can cause bone loss. A new study has found that anticancer drugs aren't the only culprits. Among 64 breast cancer patients referred to a bone health clinic, 78 percent had at least one other cause of b... (Leggi Articolo)
- Renal impairment associated with Zometa
- There is a well-known risk of deterioration in renal function with intravenous bisphosphonates administered at a rapid infusion rate. ADRAC ( Adverse Drug Reactions Advisory Committee ) has received few reports of renal impairment or failure with Pamidronate ( Aredia ) and the oral bisphosphona... (Leggi Articolo)
- Bisphosphonates associated with osteonecrosis of the jaw
- Most of the cases of osteonecrosis of the jaw are seen in oncology patients that, besides intravenous bisphosphonates, have received chemotherapy in the long term for their base disease with or without intermittent cycles of steroids. Mechanism of action begins to be recognized, the bisphosp... (Leggi Articolo)
- Osteoporosis: Teriparatide not cost-effective compared with Alendronate
- Researchers at the Stanford University School of Medicine have found that a new osteoporosis drug, called Teriparatide ( Forteo ), is not cost-effective compared with the most commonly prescribed osteoporosis medication, Alendronate ( Fosamax ). While the average wholesale price of alendronate... (Leggi Articolo)
- Post menopausal women: prevention of secondary osteoporotic fractures
- The National Institute for Clinical Excellence ( NICE ) has issued guidance to the NHS in England and Wales on the use of bisphosphonates ( Alendronate, Etidronate, Risedronate ), Raloxifene and Teriparatide for the prevention of further osteoporotic fragility fractures in postmenopausal women wh... (Leggi Articolo)
- Osteonecrosis of the jaw and bisphosphonates
- Bisphosphonates are drugs commonly used to prevent and treat osteoporosis in post-menopausal women. They are widely used in the management of advanced cancers that have metastasized to the bone, where the disease often causes bone pain and possibly even fractures. Several cancers can metast... (Leggi Articolo)
- Prolia increases bone mineral density in postmenopausal women
- Twice-yearly subcutaneous injections of Denosumab ( 60 mg; Prolia ) increased bone mineral density ( BMD ) in the lumbar spine, total hip, distal 1/3 radius and total body compared to placebo at 24 months. The ongoing, multi-center, phase 2 dose-ranging trial includes results from 337 healthy ... (Leggi Articolo)
